Natural compound may fight rheumatoid arthritis at its source
A study published in Engineering suggests that a natural compound called obakulactone (OL) may effectively treat rheumatoid arthritis by targeting the ACOT1 enzyme. Experiments in rats showed that the compound reduced joint swelling and restored cartilage structure by balancing fatty acid metabolism.
Why it matters
Identifying new molecular targets like ACOT1 could lead to more effective, natural-based therapies for chronic inflammatory diseases like rheumatoid arthritis.
A natural compound called obakulactone (OL) may offer a new way to treat rheumatoid arthritis (RA), according to a study published in Engineering . OL is a tetracyclic triterpenoid isolated from Phellodendri cortex . Researchers found that it reduced signs of arthritis by promoting the breakdown of acyl coenzyme A thioesterase 1 (ACOT1) through the ubiquitin‒proteasome pathway and by restoring the balance of unsaturated fatty acids.
The findings help explain how OL acts on rheumatoid arthritis at the molecular level. They also identify ACOT1 as a possible new drug target and suggest that correcting disrupted fatty acid metabolism could become a useful strategy for treating RA.
Obakulactone Reduced Joint Swelling and Damage
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in